PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7112858

[Initial changes in the optic disk and central visual field in open-angle glaucoma].

L P Kozlova·N A Sporova·R N Voĭtova·A A Babaian·T I Balishanskaia
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Glaucoma, Open-AngleHumansOphthalmoscopyOptic DiskPhotogrammetryVisual Field TestsVisual FieldsComparative StudyEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L P Kozlova, N A Sporova, R N Voĭtova, A A Babaian, T I Balishanskaia. [Initial changes in the optic disk and central visual field in open-angle glaucoma].. https://pubmed.ncbi.nlm.nih.gov/7112858/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Laser trabeculoplasty for primary open-angle glaucoma.

The purpose of the Committee on Ophthalmic Procedure Assessments is to evaluate on a scientific basis new and existing ophthalmic tests, devices, and procedures for their safety, efficacy, clinical effectiveness, and appropriate uses. Evaluations include examination of available literature, epidemiological analyses when appropriate, and compilation of opinions from recognized experts and other interested parties. After appropriate review by all contributors, including legal counsel, assessments are submitted to the Academy's Board of Trustees for consideration as official Academy policy.

Glaucoma, Open-Angle↗
PubMed1996

Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.

Latanoprost is an ester prodrug analogue of prostaglandin F2 alpha which effectively reduces intraocular pressure (IOP) by increasing uveoscleral outflow rather than altering conventional trabeculo-canalicular) aqueous outflow. The IOP-lowering effect of latanoprost lasts for 20 to 24 hours after a single dose, which allows a single daily dosage regimen. Data from 4 randomised double-masked multicentre studies indicate that a once daily dose of topical latanoprost 0.005% is as effective as timolol 0.5% twice daily in the treatment of patients with primary open-angle glaucoma or ocular hypertension. A number of studies also demonstrate that latanoprost enhances IOP-lowering effects when applied in combination with other antiglaucoma agents. Latanoprost is well tolerated with no, or barely detectable, conjunctival hyperaemia, and, unlike timolol, is not associated with systemic adverse effects. However, 3 to 10% of patients treated with latanoprost 0.005% have shown increased iris pigmentation after 3 to 4.5 months' treatment. In summary, the available data show that latanoprost is a potent IOP-lowering agent with a number of positive features including a single daily dosage regimen, a novel mechanism of action that enhances the IOP-lowering effect of contemporary agents, and a lack of systemic adverse effects. These properties suitably poise latanoprost for a prominent position in the management of patients with primary open-angle glaucoma and ocular hypertension.

Glaucoma, Open-Angle↗
PubMed1996

The psychometric function and reaction times of automated perimetry in normal and abnormal areas of the visual field in patients with glaucoma.

PURPOSE: To study the relationship of reaction time to the psychometric function in normal subjects, normal sensitivity test locations in patients with glaucoma, and test locations with 10 to 20 dB loss in patients with glaucoma. METHODS: The authors tested 10 patients with glaucoma and 10 age-matched normal volunteers with the Humphrey perimeter, first with program 24-2 and then with the method of constant stimuli to generate frequency of seeing curves. At two widely separated visual field locations on the program 24-2 grid, they presented stimuli in 2-dB intervals, 10 dB either side of the program 24-2 threshold, at 0 dB and 60 dB (15 repetitions per intensity). For the patients with glaucoma, they chose a visual field location with normal sensitivity and a location in an area of 10 to 20 dB loss. RESULTS: Analysis of variance with post hoc t-tests showed that reaction time (RT) at the 0-dB intensity was prolonged by approximately 90 msec in the abnormal sensitivity test location of patients with glaucoma compared to the control and the glaucoma normal sensitivity groups (P<0.0001). However, this difference was accounted for by only 4 of the 10 patients with glaucoma, reaching 100% of stimuli seen with the brightest stimulus at the moderately damaged test location. Reaction time at the frequency of seeing 50% estimated threshold showed no significant differences among the groups. Prolongation of RT from the 0-dB value was analyzed as a function of increasing attenuation of stimulus intensity. The results fit the equation RT = a + b(Intensity3) for all groups. CONCLUSIONS: There is no significant difference in RT between normal subjects and patients with glaucoma either at threshold or to suprathreshold stimuli. Reaction time increases after a power function with increasing attenuation of stimulus intensity up to the threshold.

Glaucoma, Open-Angle↗